Na Li, MD
Gastroenterology · Columbus, OHNPI 1649416504
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,000 of the $1,144 with a category attached, or 87.4%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 87.4% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in OH, where the typical reported total is $2,203.
Across 3 payments — averaging $381.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Gilead$88
- AbbVie$56
Across 372 payments — averaging $3694.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$670K
- Intercept Pharmaceuticals, Inc.$485K
- Boehringer Ingelheim International GmbH$99K
- Madrigal Pharmaceuticals$83K
- Alnylam Pharmaceuticals Inc.$19K
- Novo Nordisk AS$18K
What the payments were for
- Speaking & faculty fees$1,00087%
- Food & beverage$14413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,000 |
| Gilead | 1 | $88 |
| AbbVie | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$1,000
How this compares
$1,144 in reported general payments places this provider in the 35th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $313,479 |
| Ondansetron Hcl | 13 | $474 |
| Omeprazole | 52 | $449 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $341 |
| Lactulose | 13 | $261 |
| Promethazine Hcl | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Columbus
- Tasos ManokasColumbus$411K
- Jeffrey LefkovitzColumbus$164K
- Adam HanjeColumbus$139K
- David LoColumbus$126K
- Shail GovaniColumbus$120K
- William SaltColumbus$87K
- Philip HartColumbus$58K
- Abdulfatah IssakColumbus$53K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.